

ExpreS²ion Biotech Holding AB
Press Release, 2018-09-06

ExpreS²ion's own Zika virus antigen products included in agreement with U.S.-based Integrated BioTherapeutics

ExpreS²ion Biotech Holding AB's fully owned subsidiary ExpreS²ion Biotechnologies ApS ("ExpreS²ion") announces that it has amended its Research & Commercial License Agreement with U.S.-based partner and licensee Integrated BioTherapeutics ("IBT") to include own ExpreS²-based products, initially a number of Zika virus antigens.

"We are thrilled that our own products are now made commercially available through IBT, starting with our Zika virus antigens. This is in line with our expanded core platform strategy, which includes development and production of our own recombinant proteins, in addition to our development and production services and licensing agreements for the ExpreS² platform," says ExpreS²ion's CEO Dr. Steen Klynsner.

As stated in July 2017, IBT is planning to launch up to five ExpreS²-based products annually in its portfolio aimed at the scientific community. The addition of ExpreS²ion's own products contributes to this estimate.

ExpreS²ion and IBT do not disclose the financial terms of the amended agreement, as it constitutes a part of both companies' general business models. However, ExpreS²ion stated in July 2017 that the Company will receive a two-digit percentage royalty based on net sales of ExpreS²-based products that IBT will develop and sell to its clients, and that the collaboration is expected to generate annual revenues of up to 1 MSEK to ExpreS²ion when fully implemented. This statement is still valid following today's announcement, but the time to implementation is expected to be shortened.

Once ready for sale, the Zika virus antigen products can be ordered directly from IBT Bioservices' website. There will also be a catalogue data sheet available. Follow this link to reach the website: <http://www.ibtbioservices.com/>

About Integrated BioTherapeutics, Inc.

Integrated BioTherapeutics, Inc., Rockville, Maryland, USA is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT's antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses. IBT's service and reagent division doing business as IBT Bioservices (www.ibtbioservices.com) produces and markets high quality recombinant proteins and antibodies primarily for infectious disease research and offers *in vitro* and *in vivo* anti-microbial testing services.

Certified Adviser

Sedermersa Fondkommission is appointed as Certified Adviser for ExpreS²ion.

For further information about ExpreS²ion Biotech Holding AB, please contact:

Dr. Steen Klynsner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS²ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on September 6, 2018.

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS², that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS²ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.